These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 18667823

  • 1. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D.
    Digestion; 2008; 77(3-4):225-35. PubMed ID: 18667823
    [Abstract] [Full Text] [Related]

  • 2. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D.
    Scand J Gastroenterol; 2008; 43(10):1202-11. PubMed ID: 18618371
    [Abstract] [Full Text] [Related]

  • 3. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
    Fukudo S, Kinoshita Y, Okumura T, Ida M, Akiho H, Nakashima Y, Nishida A, Haruma K.
    Gastroenterology; 2016 Feb; 150(2):358-66.e8. PubMed ID: 26551550
    [Abstract] [Full Text] [Related]

  • 4. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
    Fukudo S, Matsueda K, Haruma K, Ida M, Hayase H, Akiho H, Nakashima Y, Hongo M.
    Neurogastroenterol Motil; 2017 Jun; 29(6):. PubMed ID: 28205278
    [Abstract] [Full Text] [Related]

  • 5. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
    Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K.
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ, Kim NY, Kwon JK, Huh KC, Lee OY, Lee JS, Choi SC, Sohn CI, Myung SJ, Park HJ, Choi MK, Bak YT, Rhee PL.
    Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Tomita T, Fukui H, Morishita D, Mori S, Oshima T, Shinzaki S, Miwa H.
    J Clin Med; 2022 Nov 22; 11(23):. PubMed ID: 36498457
    [Abstract] [Full Text] [Related]

  • 8. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
    Qi Q, Zhang Y, Chen F, Zuo X, Li Y.
    BMC Gastroenterol; 2018 Jan 08; 18(1):5. PubMed ID: 29310568
    [Abstract] [Full Text] [Related]

  • 9. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG.
    Am J Gastroenterol; 2007 Aug 08; 102(8):1709-19. PubMed ID: 17509028
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.
    Zheng Y, Yu T, Tang Y, Xiong W, Shen X, Jiang L, Lin L.
    PLoS One; 2017 Aug 08; 12(3):e0172846. PubMed ID: 28291778
    [Abstract] [Full Text] [Related]

  • 11. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).
    Min YW, Rhee PL.
    Therap Adv Gastroenterol; 2015 May 08; 8(3):136-42. PubMed ID: 25949526
    [Abstract] [Full Text] [Related]

  • 12. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.
    Fukudo S, Kinoshita Y, Okumura T, Ida M, Hayashi K, Akiho H, Nakashima Y, Haruma K.
    J Gastroenterol; 2016 Sep 08; 51(9):874-82. PubMed ID: 26800997
    [Abstract] [Full Text] [Related]

  • 13. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
    Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM.
    Arch Intern Med; 2001 Jul 23; 161(14):1733-40. PubMed ID: 11485506
    [Abstract] [Full Text] [Related]

  • 14. Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1.
    Shiotani A, Kusunoki H, Ishii M, Imamura H, Manabe N, Kamada T, Hata J, Merchant JL, Haruma K.
    Neurogastroenterol Motil; 2015 Jan 23; 27(1):82-91. PubMed ID: 25428414
    [Abstract] [Full Text] [Related]

  • 15. Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome.
    Chiba T, Yamamoto K, Sato S, Suzuki K.
    Clin Exp Gastroenterol; 2013 Jan 23; 6():123-8. PubMed ID: 23922505
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS.
    Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M.
    Inflammopharmacology; 2007 Feb 23; 15(1):5-9. PubMed ID: 17323187
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R, Nikfar S, Abdollahi M.
    Clin Ther; 2008 May 23; 30(5):884-901. PubMed ID: 18555935
    [Abstract] [Full Text] [Related]

  • 18. [Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea].
    Hirata T, Funatsu T, Keto Y, Akuzawa S, Akiho H, Nishida A, Sasamata M, Miyata K.
    Nihon Yakurigaku Zasshi; 2009 May 23; 133(5):281-91. PubMed ID: 19443966
    [No Abstract] [Full Text] [Related]

  • 19. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
    Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ.
    Am J Gastroenterol; 2004 Nov 23; 99(11):2195-203. PubMed ID: 15555002
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea.
    Ida M, Nishida A, Akiho H, Nakashima Y, Matsueda K, Fukudo S.
    Biopsychosoc Med; 2017 Nov 23; 11():7. PubMed ID: 28293280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.